Experimental drug plus radiation shows promise for rare sarcoma
NCT ID NCT06025747
First seen Nov 01, 2025 · Last updated Jun 23, 2026 · Updated 35 times
Summary
This early-phase trial is testing whether the drug abemaciclib, when given with radiation therapy before surgery, can safely shrink high-risk retroperitoneal liposarcomas. About 18 adults with this rare cancer will receive the combination to find the best dose and check for side effects. The goal is to see if this approach makes tumors easier to remove and improves outcomes.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LIPOSARCOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Fred Hutch/University of Washington Cancer Consortium
RECRUITINGSeattle, Washington, 98109, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
abemaciclib (Verzenio) and radiation therapy
What this could lead to
If successful, this could lead to a new treatment option that shrinks tumors before surgery, potentially improving outcomes for people with this rare sarcoma.
What could go wrong
This is a very early, small phase 1 trial with only 18 participants, so results may not apply broadly. The combination may cause side effects or fail to shrink tumors as hoped.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.